Circulating mediators of bone remodeling in psoriatic arthritis: implications for disordered osteoclastogenesis and bone erosion

Table 3 Cellular markers of bone remodeling and bone pathology scores in patients with PsA

	Median (range)	XR erosion score	XR narrowing score	Combined XR score	Number of joints with pencil-in-cup deformities on XR	Number of joints with new bone formation on XR	Total hip BMD Tscore
Percentage CD11b⁺/CD14⁺ cells (% all PBMCs)	3.3 (0.04-9.0)	0.35^a	0.36^a	0.38^a	0.11	0.03	-0.20
TRAP⁺ MNCs (per 10⁶ PBMCs)^c	29 (0-913)	0.31	0.41^a	0.37^a	0.34^a	0.00	-0.18
TRAP⁺ MNCs adjusted for number of CD11b⁺/CD14⁺ cells^c	9 (0-454)	0.18	0.21	0.17	0.28	0.00	-0.10
Number of pits (per 10⁶ PBMCs)	0 (0-500)	0.43^a	0.48^b	0.46^b	0.41^a	0.00	-0.33
Number of pits adjusted for number of CD11b⁺/CD14⁺ cells^c	0 (0-371)	0.45^b	0.49^b	0.47^b	0.45^b	0.01	-0.30

^aP < 0.05; ^bP < 0.01; ^cafter culture with RANKL and M-CSF. Spearman r values for correlations between cellular markers and measures of bone pathology. BMD, bone mineral density; M-CSF, macrophage-colony stimulating factor; MNCs, multinucleated cells; PBMCs, peripheral blood mononuclear cells; RANKL, receptor activator of nuclear factor-κB ligand; TRAP, tartrate-resistant acid phosphatise; XR, x-ray.

ISSN: 1478-6362